The deubiquitinating enzyme USP13 as a specific therapeutic target in glioblastoma Vrije Universiteit Brussel
Currently, most patients die in the months following their diagnoses.
Chemotherapeutic agents for this cancer are scarce and non-specific.
Temozolomide is almost systematically used to treat glioblastoma. Its mechanism of action is based on its ability to alkylate/methylate DNA, damaging it, and killing the tumor along with normal cells.